Corey Rosen
Allergan Beats Stock-Drop Lawsuit
In In re Allergan ERISA Litigation, No. 2:17-cv-01554-SDW-LDW, (D.-N.J., July 2., 2018), a judge dismissed a suit against Allergan and its directors in a 401(k) stock-drop suit concluding that the plaintiffs did not show that the defendants were plan fiduciaries. The court ruled that it was insufficient to allege that the defendants were fiduciaries because they appointed the independent plan trustee. The ruling does not refer to a duty to monitor the trustee, but focuses on whether the defendants took action that caused the trustee, in this case, not to remove the stock. The court found insufficient evidence for this claim. Defendants were also not fiduciaries as a result of their securities filings. The court also ruled that the plaintiffs did not allege reasonable alternative courses of action the company or its executives could have taken in light of the company’s alleged antitrust violations. Disclosing these, the court said, could have done more harm than good.